Heterologous expression of ␣ 1D -adrenergic receptors (␣ 1D -ARs) in most cell types results in intracellular retention and little or no functionality. We showed previously that heterodimerization with ␣ 1B -ARs promotes surface localization of ␣ 1D -ARs. Here, we report that the ␣ 1B -/␣ 1D -AR interaction has significant effects on the pharmacology and signaling of the receptors, in addition to the effects on trafficking described previously. Upon coexpression of ␣ 1B -ARs and epitope-tagged ␣ 1D -ARs in both human embryonic kidney 293 and DDT 1 MF-2 cells, ␣ 1D -AR binding sites were not detectable with the ␣ 1D -AR selective antagonist 8-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-8-azaspiro [4,5]decane-7,9-dione (BMY 7378), despite the ability to detect ␣ 1D -AR protein using confocal microscopy, immunoprecipitation, and a luminometer cell-surface assay. However, the ␣ 1B -AR-selective mutant F18A conotoxin showed a striking biphasic inhibition in ␣ 1B /␣ 1D -AR-expressing cells, revealing that ␣ 1D -ARs were expressed but did not bind BMY 7378 with high affinity. Studies of norepinephrine-stimulated inositol phosphate formation showed that maximal responses were greatest in ␣ 1B /␣ 1D -AR-coexpressing cells. Stable coexpression of an uncoupled mutant ␣ 1B -AR (⌬12) with ␣ 1D -ARs resulted in increased responses to norepinephrine. However, Schild plots for inhibition of norepinephrine-stimulated inositol phosphate formation showed a single low-affinity site for BMY 7378. Thus, our findings suggest that ␣ 1B /␣ 1D -AR heterodimers form a single functional entity with enhanced functional activity relative to either subtype alone and a novel pharmacological profile. These data may help to explain why ␣ 1D -ARs are often pharmacologically undetectable in native tissues when they are coexpressed with ␣ 1B -ARs.
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An emerging paradigm in the field of pharmacology is that G-protein-coupled receptors (GPCRs) can form homo-and heterodimers, resulting in the formation of unique multiprotein complexes that have altered trafficking, signaling, and pharmacological properties (Milligan et al., 2004; Terrillon and Bouvier, 2004; Prinster et al., 2005) . In fact, recent data have raised the possibility that homodimerization may be a ubiquitous process that is required for the proper expression of GPCRs (Canals et al., 2004; Kaykas et al., 2004; Salahpour et al., 2004) . A growing number of reports implicating a clinical role for GPCR dimerization in opiate analgesia (Jordan and Devi, 1999) , human immunodeficiency virus infection (Rodriguez-Frade et al., 2004) , and vitreoretinopathy (Kaykas et al., 2004) highlight the need to continue characterizing the mechanisms and properties of novel GPCR dimers.
Numerous studies have now shown that GPCR heterodimerization is essential for proper expression and function of GABA B (Marshall et al., 1999) , taste (Nelson et al., 2001) , olfactory (Hague et al., 2004b) , and ␣ 1D -adrenergic receptors (ARs) (Hague et al., 2004c) . The most convincing and thoroughly studied example to date of GPCR heterodimerization involves the formation of functional GABA B receptors. It is now clear that GABA B R1 and GABA B R2 must heterodimerize to ensure trafficking of GABA B receptors to the cell surface (Kaupmann et al., 1998; Marshall et al., 1999) at least partially through the masking of an endoplasmic reticulum (ER) retention signal located in the carboxylterminal tail of GABA B R1 receptors (Margeta-Mitrovic et al., 2000) . In addition, the formation of sweet taste receptors requires heterodimerization of T1R2 and T1R3 receptors (Nelson et al., 2001) , and the M71 mouse olfactory receptor can achieve surface expression and become functional when heterodimerized with the ␤ 2 -AR (Hague et al., 2004b) . In previous studies, we showed that ␣ 1D -AR heterodimerization with ␣ 1B -ARs was required to promote surface expression of the intracellularly retained ␣ 1D -AR (Hague et al., 2004c) . These examples provide compelling evidence for GPCR heterodimerization in regulating GPCR cellular localization. However, with a handful of exceptions, such as ␦-and -opioid (Jordan and Devi, 1999) , D2 and D3 dopamine (Maggio et al., 2003) , and ␣ 2A -/␤ 1 -adrenergic receptors (Xu et al., 2003) , few examples of receptor heterodimerization causing significant pharmacological changes have been reported to date.
One longstanding mystery in the ␣ 1 -AR field has been the inability to detect ␣ 1D -AR binding sites in intact tissues with the ␣ 1D -AR-selective antagonist BMY 7378 (Yang et al., , 1998 , despite the fact that ␣ 1D -AR mRNA is as widely expressed throughout the body as mRNA for the ␣ 1A -AR and ␣ 1B -AR subtypes (Rokosh et al., 1994; Alonso-Llamazares et al., 1995; Scofield et al., 1995) . Previous studies have suggested that ␣ 1D -AR mRNA may only be translated in response to specific stimuli, such as a loss of other ␣ 1 -AR subtypes (Turnbull et al., 2003) or hypertension (Ibarra et al., 2000) . On the other hand, ␣ 1D -AR mRNA may be widely translated, but ␣ 1D -AR ligand binding may be masked or may exhibit altered properties in certain tissues. It has long been apparent that the ␣ 1D -AR is the most poorly coupled of all ␣ 1 -ARs (Theroux et al., 1996) and that one possible reason could be that it functions poorly without a binding partner, such as the ␣ 1B -AR. We report in this study that ␣ 1D -ARs coexpressed with ␣ 1B -ARs are undetectable with BMY 7378. Using immunochemical, biochemical, and pharmacological approaches, we found that ␣ 1D -/␣ 1B -AR heterodimers act as a single entity with novel pharmacological properties, and each receptor subunit contributes a specific functional component to the complex.
Materials and Methods
Materials. Materials were obtained from the following sources: cDNAs for the wild-type human ␣ 1A -AR (Hirasawa et al., 1993) and human ␣ 1D -AR C-terminally tagged GFP constructs in pEGFP-N3 (Xu et al., 1999) were generously provided by Dr. Gozoh Tsujimoto (National Children's Hospital, Tokyo, Japan), human ␣ 1B -AR cDNA (Ramarao et al., 1992 ) was a gift from Dr. Dianne Perez (Cleveland Clinic, Cleveland, OH), and human ␣ 1D -AR cDNA was cloned in our laboratory (Esbenshade et al., 1995) ; FLAG/GFP-tagged human ␣ 1D -ARs and ⌬ 1-79 ␣ 1D -ARs were created previously in our laboratory (Vicentic et al., 2002; Hague et al., 2004a) . Hamster ⌬12␣ 1B -AR in pCMV was a gift from Dr. Myron Toews (University of Nebraska Medical Center, Omaha, NE); -T1A and F18A mutants were a gift from Dr. Richard Lewis (Xenome Ltd., Queensland, Australia); HEK293 and DDT 1 MF-2 cells were from American Type Culture Collection (Manassas, VA); 5-methylurapidil, niguldipine, BMY 7378, (Ϫ)-norepinephrine bitartrate, Dowex 1 Resin, horseradish peroxidase-conjugated anti-Flag M2 antibody, and bovine serum albumin were from Sigma-Aldrich (St. Louis, MO); [myo-3 H]inositol was from American Radiolabeled Chemicals (St. Louis, MO); Lipofectamine 2000 transfection reagent, fetal bovine serum, and penicillin/streptomycin were from Invitrogen (Carlsbad, CA); enzymelinked immunosorbent assay enhanced chemiluminescence was from Pierce Chemical (Rockford, IL); Vectashield mounting medium was from Vector Laboratories (Burlingame, CA); and Dulbecco's modified Eagle's medium was from Cellgro-Mediatech (Herndon, VA).
Cell Culture and Transfection. HEK293 and DDT 1 MF-2 cells were propagated in Dulbecco's modified Eagle's medium with sodium pyruvate supplemented with 10% heat inactivated fetal bovine serum, 100 g/ml streptomycin, and 100 U/ml penicillin at 37°C in a humidified atmosphere with 5% CO 2 . Confluent plates were subcultured at a ratio of 1:5 for transfection. HEK293 and DDT 1 MF-2 cells were transfected with 10 g of DNA of each construct for 3 h using Lipofectamine 2000 transfection reagent, and cells were used for experimentation 48 to 72 h after transfection. Stable transfection of receptors was obtained by selection with 400 g/ml G418 (pcDNA3.1, pDT, and pEGFP vectors) or 200 g/ml hygromycin (pREP4 vector).
Luminometer-Based Surface-Expression Assay. DDT 1 MF-2 cells were split into poly(D-lysine)-coated 35-mm dishes and incubated with horseradish peroxidase-conjugated M2-anti-FLAG antibody in blocking buffer, and cell-surface luminescence was determined using a method described previously (Hague et al., 2004c) .
Laser Confocal Microscopy. Cells were grown on sterile coverslips, fixed for 30 min with 2% paraformaldehyde in 0.1 M phosphate buffer, washed, mounted, and scanned with a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss GmbH, Heidelberg, Germany) as described previously (Hague et al., 2004c) . For detecting GFP, fluorescein isothiocyanate fluorescence was excited using an argon laser at a wavelength of 488 nm, and the absorbed wavelength was detected for 510 to 520 nm for GFP.
Immunoprecipitation/Immunoblotting. DDT 1 MF-2 cells expressing FLAG-␣ 1D GFP ARs were harvested by scraping in ice-cold phosphate-buffered saline (PBS) and washed by repeated centrifugation and homogenization. Cell lysates were solubilized, immunoprecipitated with anti-FLAG M2 affinity resin, and probed using anti-FLAG M2 monoclonal antibodies as described previously .
Radioligand Binding. Confluent 150-mm plates were washed with PBS (20 mM NaPO 4 and 154 mM NaCl, pH 7.6) and harvested by scraping. Cells were collected by centrifugation, homogenized with a Polytron homogenizer (Kinematica, Basel, Switzerland), centrifuged at 30,000g for 20 min, and resuspended in PBS. Radioligand binding sites were measured by saturation analysis of specific binding of the ␣ 1 -adrenergic receptor antagonist radioligand 125 I-BE 2254 (20-800 pM). Nonspecific binding was defined as binding in the presence of 10 M phentolamine. The pharmacological specificity of radioligand binding sites was determined by displacement of 125 I-BE 2254 (50-70 pM) by prazosin, 5-MU, niguldipine, NE, F18A, and BMY 7378, and data were analyzed using nonlinear regression.
Measurement of [ 3 H]InsP
Formation. Accumulation of [ 3 H]inositol phosphates (InsPs) was determined in confluent 96-well plates by a protocol described previously (Hague et al., 2004c) . After prelabeling, medium containing [myo-3 H]inositol was removed, and 100 l of Krebs-Ringer bicarbonate buffer (120 mM NaCl, 5.5 mM KCl, 2.5 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 1.2 mM MgCl 2 , 20 mM NaHCO 3 , 11 mM glucose, and 0.029 mM Na 2 EDTA) containing 10 mM LiCl was gently added to each well. Cells were incubated with or without 100 M NE for 60 min. For studies using BMY 7378, antagonist was added to cells for 30 min before the addition of agonist. The reaction was stopped by the addition of 100 l of 20 mM formic acid, and samples were sonicated for 10 s. Samples were subjected to anion exchange chromatography to isolate [ 3 H]InsPs, which were quantified by scintillation counting.
Data Analysis and Statistics. Radioligand binding and [ 3 H]InsP formation data were calculated as means Ϯ S.E.M. and statistical comparisons used GraphPad Prism Software (GraphPad Software Inc., San Diego, CA). Schild plots were calculated according to the method described originally by Arunlakshana and Schild (1959) .
Results
␣ 1D -AR Binding Sites Are Undetectable with BMY 7378 in DDT 1 MF-2 Cells Expressing ␣ 1D -AR Protein. We have shown previously that intracellular ␣ 1D -ARs require heterodimerization with ␣ 1B -ARs to promote their expression at the cell surface (Hague et al., 2004c) . Because DDT 1 MF-2 cells endogenously express ␣ 1B -ARs at approximately 300 to
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Hague et al. FLAG-␣ 1D -GFP ARs to use as a model system for functional and pharmacological characterization of ␣ 1B -/␣ 1D -AR heterodimers. As expected, confocal microscopy ( Fig. 1A ) and a luminometer-based cell-surface assay (Fig. 1B) indicated that ␣ 1D -ARs were quantitatively expressed at the cell surface. In support of these findings, immunoblotting for FLAG revealed that FLAG-␣ 1D -GFP protein was expressed (Fig.  1C) , suggesting that a significant number of ␣ 1D -ARs were expressed at the cell surface. Although Western blots are only semiquantitative, careful titration of N-truncated ␣ 1D -AR binding site expression with the density of signal on Western blots suggests that this should translate into ϳ600 fmol/mg of protein of ␣ 1D -AR binding sites (data not shown). Therefore, we expected to see corresponding increases in the ␣ 1 -AR B max and the appearance of ␣ 1D -AR binding sites. However, in saturation binding experiments, we found no significant differences in receptor expression levels between untransfected and ␣ 1D -AR expressing DDT 1 MF-2 cells (Fig.  1D ). In addition, ␣ 1D -AR binding sites were undetectable in 125 I-BE 2254 competition binding experiments using the ␣ 1D -AR selective antagonist BMY 7378. Only a single population of ␣ 1B -AR low-affinity binding sites consistent with previously observed values at ␣ 1B -ARs (Goetz et al., 1995) was observed in both wild-type and ␣ 1D -AR transfected cell lines. Thus, our confocal and biochemical data suggested that ␣ 1D -ARs were expressed at the plasma membrane after transfection into DDT 1 MF-2 cells. However, our findings from radioligand binding experiments suggested that ␣ 1D -ARs were not detectable pharmacologically.
␣ 1D -AR Binding Sites Are Undetectable with BMY 7378 in HEK293 Cells Coexpressing ␣ 1D -/␣ 1B -ARs. From our data obtained in DDT 1 MF-2 cells, we hypothesized that our inability to detect ␣ 1D -AR binding sites might be caused by low ␣ 1D -AR expression levels, despite the fact that the Western blots suggested that they should be easily detectable. Therefore, we chose to switch to HEK293 cells as a model to characterize ␣ 1B -/␣ 1D -AR heterodimers, because in previous studies, we have found that extremely high receptor expression levels can be obtained using this cell line Hague et al., 2004a,c) . To create a HEK293 cell line stably coexpressing ␣ 1B -/␣ 1D -ARs, we first transfected HA-␣ 1B -ARs in the pREP4 vector and selected with hygromycin until only resistant cells remained. After selection, we confirmed the presence of HA-␣ 1B -ARs by performing 125 I-BE 2254 competition binding experiments using BMY 7378, which detected a homogenous population of low-affinity binding sites ( Fig. 2A) . FLAG-␣ 1D -GFP ARs were then stably transfected into HEK293 cells alone or into HEK293 cells stably expressing HA-␣ 1B -ARs.
125 I-BE 2254 competition ␣ 1B /␣ 1D -AR Heterodimers Form a Single Functional Entity binding with BMY 7378 identified a single population of high-affinity BMY 7378 binding sites in HEK293 cells expressing FLAG-␣ 1D -GFP alone. However, similar to our observations in DDT 1 MF-2 cells, BMY 7378 detected only a single population of low-affinity binding sites in HEK293 cells coexpressing FLAG-␣ 1D -GFP and HA-␣ 1B -ARs ( Fig. 2A) . A screen of a panel of ␣ 1 -AR-selective antagonists (Table 1) provided no further evidence for the presence of ␣ 1D -AR binding sites. The ␣ 1A -AR-selective antagonists 5-MU and niguldipine recognized a low-affinity binding site, and the nonselective ligands prazosin, BE 2254, and NE all bound within the range of affinities reported previously. Therefore, to determine whether ␣ 1D -ARs were expressed in this cell line using an alternative method, HEK293 cells coexpressing FLAG-␣ 1D -GFP and HA-␣ 1B -ARs were fixed on coverslips and examined using confocal microscopy. As shown in Fig.  2B , FLAG-␣ 1D -GFP ARs were quantitatively expressed at the plasma membrane in this cell line, which was in direct contrast to our radioligand binding data suggesting that ␣ 1D -ARs were not expressed. Finally, Western blots from cell lysates were then immunoprecipitated and run on SDS gels and were compared with Western blots from HEK293 cells expressing N-truncated ␣ 1D -ARs at approximately 450 fmol/mg of protein (Fig. 2C) . The results from our biochemical and confocal studies indicated that ␣ 1D -ARs were present when coexpressed with ␣ 1B -ARs and should have been forming functional binding sites, yet our pharmacological data indicate that they were not.
To ensure that ␣ 1D -ARs would be expressed at high levels, we used a previously generated HEK293 cell subclone expressing a high density of wild-type (WT) human ␣ 1D -AR binding sites (B max ϭ 920 fmol/mg of protein; data not shown). With this high ␣ 1D -AR expression level, we hypothesized that overexpressing ␣ 1B -ARs in this cell line would still allow for easy detection of ␣ 1D -AR binding sites. WT human ␣ 1A -or ␣ 1B -ARs in the pREP4 vector were then transfected into the high-expression WT ␣ 1D -AR subclone and selected using hygromycin. B max values were then determined using 125 I-BE 2254 saturation binding. As shown in Fig. 3A , HEK293 cells transfected with empty pREP4 alone had no significant increase in ␣ 1D -AR expression levels (B max ϭ 1204 fmol/mg of protein), whereas the B max value in ␣ 1A -/␣ 1D -AR-coexpressing cells increased to 1845 fmol/mg of protein (Table 2 ). It is interesting that the B max in ␣ 1B -/␣ 1D -AR-coexpressing cells was unchanged at 1070 fmol/mg of protein, which was not significantly different from the B max in HEK293 cells expressing ␣ 1D -ARs alone. From these findings, we hypothesized that detection of ␣ 1D -AR binding sites with BMY 7378 would be possible in this ␣ 1B -/␣ 1D -AR coexpression cell line. As shown in Fig. 3B , 125 I-BE 2554 competition binding with BMY 7378 revealed the expected result of a heterogeneous population of high-and low-affinity binding sites in ␣ 1A -/␣ 1D -AR-coexpressing HEK293 cells and a single population of high-affinity binding sites in ␣ 1D -AR-expressing cells with empty pREP4 vector. However, BMY 7378 recognized only a single population of low-affinity binding sites in ␣ 1B -/␣ 1D -AR-coexpressing cell lines. These findings have three possible explanations: either 1) all previously expressed ␣ 1D -ARs had been replaced with transfected ␣ 1B -ARs; 2) ␣ 1B -/␣ 1D -ARs were both expressed and formed a heterodimer that has low affinity for BMY 7378; or 3) the presence of ␣ 1B -ARs alters the structure of ␣ 1D -ARs such that they cannot bind 125 I-BE 2554. A -T1A Mutant Peptide Reveals Multiple Binding Sites in HEK293 Cells Coexpressing ␣ 1B -/␣ 1D -ARs. We have previously characterized a conotoxin peptide -T1A isolated from the sea snail to be an ␣ 1B -AR subtype-selective antagonist that acts noncompetitively at the ␣ 1B -and com- 
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petitively at the ␣ 1A -and ␣ 1D -AR subtypes (Chen et al., 2004) . Taken from its differential modes of inhibition at the ␣ 1 -AR subtypes, it is likely that -T1A binds to regions of the ␣ 1 -ARs other than the conserved catecholamine binding pocket. -T1A is a noncompetitive inhibitor of ␣ 1B -ARs but competitively inhibits ␣ 1D -ARs (Chen et al., 2004) . Figure 4A demonstrates that this peptide is in fact a competitive inhibitor in HEK293 cells coexpressing ␣ 1B /␣ 1D -ARs. An alanine mutant of -T1A, F18A, demonstrated significant selectivity between the ␣ 1B -and ␣ 1D -AR subtypes (ϳ20-fold). Therefore, we performed competition binding experiments using F18A in the hope that it would distinguish between ␣ 1B -AR and ␣ 1D -AR binding sites. As shown in Fig. 4 , we found that F18A recognized a single population of low-affinity binding sites in HEK293 cells expressing ␣ 1D -ARs and a heterogeneous population of low-affinity binding sites in the ␣ 1A -/␣ 1D -AR coexpressing HEK293 cells (Fig. 4) . F18A unexpectedly recognized a mixture of high-and low-affinity binding sites in HEK293 cells cotransfected with ␣ 1B -/␣ 1D -ARs (Fig. 3C) . Approximately 66% of the binding sites were high affinity, with pIC 50 values of Ϫ9.0, whereas the remaining 34% of the binding sites were low affinity, with pIC 50 values of Ϫ7.0 (Table 2) . Therefore, these data suggest that F18A can recognize multiple binding sites in HEK293 cells cotransfected with ␣ 1D -AR and ␣ 1B -AR receptor subtypes, whereas BMY 7378 recognizes only a single population of low-affinity binding sites.
Coexpression of N-Truncated ␣ 1D -ARs with ␣ 1B -ARs Reveals ␣ 1D -AR Binding Sites. Previous reports from our laboratory (Hague et al., 2004a,c) and others (McCune et al., 2000; Chalothorn et al., 2002) have demonstrated that ␣ 1D -ARs are primarily intracellular when expressed alone but can be trafficked to the cell surface upon N-terminal truncation (Hague et al., 2004a) or coexpression with ␣ 1B -ARs (Hague et al., 2004c) . However, the data shown above suggest that although ␣ 1B -ARs can heterodimerize and traffic ␣ 1D -ARs to the cell surface, this does not result in an increase in binding site density or ␣ 1D -AR binding sites. Therefore, one potential interpretation of these findings is that ␣ 1B -/␣ 1D -AR heterodimers form a single receptor complex, resulting in the formation of a novel binding pocket that binds BMY 7378 with low affinity. To test this hypothesis, we coexpressed N-truncated (⌬ 1-79 ) ␣ 1D -ARs with ␣ 1B -ARs in HEK293 cells. Previous work revealed that N-truncated ␣ 1D -ARs are capable of forming heterodimers with ␣ 1B -ARs but do not require ␣ 1B -AR coexpression for trafficking to the cell surface (Hague et al., 2004a) . Thus, we predicted that coexpressing ⌬ 1-79 ␣ 1D -ARs with ␣ 1B -ARs may result in the expression of a mixed population of high-and low-affinity BMY 7378 binding sites, because N-truncated ␣ 1D -ARs do not depend on ␣ 1B -ARs for cell-surface trafficking like the wild-type ␣ 1D -ARs do. We created multiple HEK293 cell lines stably expressing ⌬ 1-79 ␣ 1D -GFP ARs and determined their receptor expression levels using 125 I-BE 2254 saturation binding. As shown in Fig. 5A , approximately 1200 to 1400 fmol/mg of protein of ⌬ 1-79 ␣ 1D -GFP ARs were expressed in each cell line, with the majority of these receptors expressed at the cell surface, as determined by confocal microscopy (Fig.  5B) . HA-␣ 1B -ARs in the pREP4 vector were then transfected into each cell line and selected with hygromycin to produce HEK293 cells coexpressing ␣ 1B -/⌬ 1-79 ␣ 1D -GFP ARs. It is interesting that cell line 1 demonstrated no significant increase in receptor density (B max ϭ 1126 fmol/mg of protein; Fig. 5A ), yet BMY 7378 distinguished a mixed population of high-(58%) and low-affinity (42%) binding sites ( Fig. 5B; Table 3 ). In direct contrast, cell line 2 demonstrated a ϳ2-fold increase in receptor density (B max ϭ 2902 fmol/mg of protein) (Fig.  5A ), but BMY 7378 recognized only a single population of low-affinity binding sites ( Fig. 5B; Table 3 ). Therefore, these findings suggest that at nonsaturating levels of ␣ 1B -AR ex- pression, there is a mixed population of ␣ 1 -ARs expressed: ⌬ 1-79 ␣ 1D -GFP ARs alone (high-affinity BMY 7378 binding sites), ␣ 1B -ARs alone, and ␣ 1B -ARs heterodimerized with ⌬ 1-79 ␣ 1D -GFP ARs (low-affinity BMY 7378 binding sites). However, at saturating levels of ␣ 1B -AR expression, only low-affinity BMY 7378 binding sites are found, which include ␣ 1B -AR and ␣ 1B -/⌬ 1-79 ␣ 1D -GFP AR heterodimers. ␣ 1B -/␣ 1D -AR Heterodimers Have Increased Maximal Responses. The data shown above suggest that ␣ 1B -and ␣ 1D -ARs form heterodimeric complexes that are characterized with low-affinity binding for the ␣ 1D -AR-selective antagonist BMY 7378. We next examined the contributions of each ␣ 1 -AR subtype to the overall signaling of the ␣ 1B -/␣ 1D -AR complex. In previous studies, we found that ␣ 1B -/␣ 1D -AR heterodimerization increased the rate of ␣ 1D -AR internalization and the maximal levels of intracellular Ca 2ϩ mobilization in response to NE stimulation but resulted in only minor increases in maximal PI hydrolysis (Hague et al., 2004c) . To further characterize the role of each ␣ 1 -AR subtype in the heterodimeric complex, we performed cell-surface assays to determine the rate of ␣ 1B -AR internalization. We found that stimulation of ␣ 1B -ARs transiently transfected in HEK293 cells resulted in a 40 to 50% loss in the number of cell-surface receptors after 30 min, with no further increase after 60 min (Fig. 6A) . Coexpressing ␣ 1B -ARs with ␣ 1D -ARs resulted in no significant difference in the rate of ␣ 1B -AR internalization, suggesting that the ␣ 1B -/␣ 1D -AR heterodimer is equally susceptible to agonist-induced endocytosis.
To further examine the functional importance of this heterodimer, we used our HEK293 cell lines stably coexpressing WT ␣ 1B -/␣ 1D -ARs to generate NE concentration-response curves for InsP formation to determine whether there were any differences in agonist potency or intrinsic activity. As shown in Fig. 6B , NE had greater intrinsic activity in cells coexpressing WT ␣ 1B -/␣ 1D -ARs than those expressing ␣ 1B -or ␣ 1D -ARs alone, or in mixtures of cells expressing ␣ 1B -and ␣ 1D -ARs alone, suggesting WT ␣ 1B -/␣ 1D -AR heterodimers act as a high-efficacy receptor complex.
␣ 1B -and ␣ 1D -ARs Have Distinct Functional Roles within the Heterodimeric Complex. To eliminate any functional responses produced by ␣ 1B -AR stimulation, we created HEK293 cell lines stably coexpressing WT ␣ 1D -ARs and an ␣ 1B -AR mutant missing three amino acids in the N-terminal portion of the third intracellular loop, which is uncoupled from functional responses (⌬12␣ 1B -ARs) but is still capable of promoting cell-surface expression of ␣ 1D -ARs (Hague et al., 2004c) . Similar to our observations in ␣ 1B -/␣ 1D -AR-coexpressing cells, BMY 7378 recognized a single population of low-affinity binding sites in cells expressing ␣ 1D -/ ⌬12␣ 1B -ARs (K I ϭ Ϫ6.27, Fig. 7B ), and NE functional responses were significantly greater than those in cells expressing ␣ 1D -ARs alone (Fig. 7A) . Because ⌬12␣ 1B -ARs do not couple to functional responses (Fig. 7A) , we hypothesized that BMY 7378 would inhibit NE functional responses in ␣ 1D -/⌬12␣ 1B -AR-coexpressing cells with high affinity. To investigate this, we incubated HEK293 cells stably coexpressing ␣ 1D -/⌬12␣ 1B -ARs with increasing concentrations of BMY 7378 for 30 min and generated NE concentration-response curves for InsP formation. Only at high concentrations (1, 3, 10, and 30 M) did BMY 7378 cause parallel shifts to the right in the NE-concentration curve (Fig. 7C) . Schild regression analysis of the data (Fig. 7D) revealed a functional affinity constant of Ϫ6.05 Ϯ 0.6 with slope not significantly different from unity. This functional affinity constant for BMY 7378 is characteristic of ␣ 1B -AR (6.0) and not ␣ 1D -AR (8.5). Therefore, these data provide strong additional evidence that BMY 7378 inhibits NE functional responses at ␣ 1B -/␣ 1D -AR heterodimers with low affinity.
Discussion
From this and previous studies, it is now clear that ␣ 1 -ARs undergo subtype-specific heterodimerization in heterologous systems. ␣ 1B -ARs can heterodimerize with both ␣ 1A -ARs (Stanasila et al., 2003; Uberti et al., 2003) and ␣ 1D -ARs Hague et al., 2004c) , whereas ␣ 1A -ARs are unable to heterodimerize with ␣ 1D -ARs . Heterodimerization of ␣ 1B /␣ 1D -ARs promotes cell-surface expression of intracellularly localized ␣ 1D -ARs. To determine the functional significance of this interaction, we further characterized the pharmacological and functional properties of ␣ 1B -/␣ 1D -AR heterodimers.
We were surprised to find that in cell lines stably coexpressing both ␣ 1B -and epitope-tagged ␣ 1D -ARs, ␣ 1D -AR expression could be detected using immunoprecipitation and confocal fluorescence microscopy but could not be detected pharmacologically with the ␣ 1D -AR-selective antagonist BMY 7378 in radioligand binding experiments. Comparison of Western blots using the epitope tags suggested that significant numbers of ␣ 1D -AR binding sites (500 fmol/mg of protein or greater) should have been present. In addition, no increase in binding-site density was observed in comparison with cells expressing either subtype alone, suggesting that ␣ 1B -/␣ 1D -AR heterodimers form a single binding site, or that the presence of ␣ 1B -ARs alters ␣ 1D -ARs such that they cannot bind 125 I-BE 2254. However, a mutant of the conotoxin -T1A (F18A) showed biphasic inhibition in cells coexpressing ␣ 1B -/ ␣ 1D -ARs. When coexpressing functionally uncoupled ␣ 1B -ARs with full-length WT ␣ 1D -ARs, the ␣ 1D -AR-selective antagonist BMY 7378 inhibited functional responses to NE with a low affinity, suggesting these two receptors are acting as individual components of a heterodimeric complex. These findings strongly suggest that ␣ 1B -and ␣ 1D -ARs heterodimerize to form a single functional entity.
One of the most surprising findings of this study was that BMY 7378 was unable to detect ␣ 1D -AR binding sites when coexpressed with ␣ 1B -ARs, despite the fact that ␣ 1D -ARs were detectable with immunoprecipitation and confocal techniques. In fact, when ␣ 1B -ARs were stably overexpressed in an HEK293 cell subclone expressing ␣ 1D -ARs at very high levels, the number of binding sites did not change, but the pharmacology of BMY 7378 shifted from a single high-to single low-affinity population of sites. This is particularly interesting given that ␣ 1D -ARs are largely undetectable with BMY 7378 in most intact tissues (Yang et al., , 1998 , despite the fact that ␣ 1D -AR mRNA is as widely expressed as the mRNAs for the ␣ 1A -AR and ␣ 1B -AR subtypes (Rokosh et al., 1994; Alonso-Llamazares et al., 1995; Scofield et al., 1995) . For example, in a recent study, mRNA for all three ␣ 1 -AR subtypes was detectable in rat submandibular gland cells. However, BMY 7378 detected only a single population of low-affinity binding sites in radioligand binding experiments (Bockman et al., 2004) , which is consistent with our findings suggesting that coexpression of ␣ 1B -and ␣ 1D -ARs results in the masking of high-affinity ␣ 1D -AR binding sites. In addition, the affinity of BMY 7378 in inhibiting phenylephrine-mediated contraction was found to be significantly increased in isolated carotid arteries from ␣ 1B -AR knockout mice (Deighan et al., 2005) , and phenylephrinestimulated increases in left ventricular-developed pressure were only inhibited by BMY 7378 in ␣ 1A -/␣ 1B -AR double knockout mice (Turnbull et al., 2003) . These unusual findings could be explained by a model wherein the knockout of ␣ 1B -ARs from native tissues results in the unmasking of ␣ 1D -AR binding sites with high affinity for BMY 7378, which would be predicted from the results of our cellular studies reported here.
There is an emerging role for dimerization in the biosynthesis and maturation of GPCRs (Bulenger et al., 2005) , and it is possible that the expression of the ␣ 1B -AR with the ␣ 1D -AR relieves a block on the intracellular or post-translational processing of the latter which allows it to be expressed on the cell surface or other aspects of protein maturational processing. Although we do not yet have evidence for such processes, further studies are likely to clarify whether this is important in this interaction.
Rat (Piascik et al., 1995) and mouse (Yamamoto and Koike, 2001 ) aortas have long been the preferred model system to study ␣ 1D -AR functional responses. From our previous studies demonstrating that ␣ 1B -AR heterodimerization with ␣ 1D -ARs promotes cell-surface expression (Hague et al., 2004c) , we expected that ␣ 1B -AR knockout mice would have diminished ␣ 1D -AR-mediated functional responses. In fact, studies of phenylephrine-stimulated contraction of aorta from ␣ 1B -AR knockout mice have given conflicting results. In the original characterization of these mice, aortic contraction was significantly diminished (Cavalli et al., 1997) . However, a subsequent study reported that aortic contraction is essentially unaltered in ␣ 1B -AR knockout mice (Daly et al., 2002) . We reported recently that ␤ 2 -ARs can also promote ␣ 1D -AR cell-surface expression, and unlike ␣ 1D -/␣ 1B -AR heterodimers, they maintain a high affinity for BMY 7378 (Uberti et al., 2005) . Therefore, one possibility is that both ␣ 1B -ARs and ␤ 2 -ARs may contribute to ␣ 1D -AR function in mouse aorta.
Accumulating evidence now suggests that each receptor within a GPCR heterodimer is responsible for a particular component of the signaling complex. Several examples of this can be observed in the class III family of GPCRs, including the GABA B (Jones et al., 1998; Kaupmann et al., 1998) and taste (Nelson et al., 2001) receptors. It is noteworthy that within the GABA B receptor heterodimer, the GABA B R2 subunit is responsible for promoting surface expression of the GABA B R1 (Jones et al., 1998; Kaupmann et al., 1998; Margeta-Mitrovic et al., 2001 ) by masking an ER retention motif in the GABA B R1 C-terminal tail (Calver et al., 2000; Margeta-Mitrovic et al., 2000) . Once properly assembled, the GABA B R1 subunit seems to be primarily responsible for agonist binding, whereas the GABA B R2 subunit couples to G-proteins (Margeta-Mitrovic et al., 2001) . It is interesting that we have found that the ␣ 1B -/␣ 1D -AR heterodimer is functionally similar to the GABA B receptor heterodimer. The ␣ 1B -AR serves to promote cell-surface expression of the ␣ 1D -AR (Hague et al., 2004c) , possibly by masking an ER retention motif in the ␣ 1D -AR N terminus (Pupo et al., 2003; Hague et al., 2004a; Petrovska et al., 2005) . In addition, it seems that within the ⌬12␣ 1B -AR/␣ 1D -AR heterodimer, the ⌬12␣ 1B -AR is primarily responsible for binding ligand, whereas the ␣ 1D -AR couples to G protein activation, but whether this is true for wild-type ␣ 1B -ARs remains to be determined. Individual receptor subunits acting as distinct components within a heterodimer complex have also been shown previously to occur with heterodimers consisting of H1 histamine and ␣ 1B -ARs (Carrillo et al., 2003) , ␤ 2 -ARs and ␦-opioid receptors (Jordan et al., 2001) , ␤ 2 -ARs and ␣ 2A -ARs (Xu et al., 2003) , and ␤ 2 -ARs and ␤ 3 -ARs (Breit et al., 2004) . Taken together, these findings suggest that GPCR heterodimers form functional complexes with distinct pharmacological and signaling properties in which each receptor subunit may be responsible for specific functions. Most of these studies have been done, by necessity, in heterologous expression systems in which receptor density is difficult to control. The functional significance of class I GPCR heterodimers has been demonstrated recently in vivo for opioid receptors using a heterodimer-selective agonist (Waldhoer et al., 2005) , consistent with the hypothesis that these complexes occur in native tissues.
The existence of ␣ 1B -/␣ 1D -AR heterodimers may seem perplexing, especially because ␣ 1B -ARs are functional when expressed alone. We have found that ␣ 1B -/␣ 1D -AR heterodimers stimulate greater maximal NE responses relative to ␣ 1B -ARs and ␣ 1D -AR expressed alone, suggesting that this heterodimer may act as a high-efficacy complex. This is similar to previous findings on ␣ 1A -/␣ 1B -AR heterodimerization in which NE responses were ϳ10-fold greater in HEK293 cells coexpressing ␣ 1A -and ␣ 1B -ARs (Israilova et al., 2004) . In addition, a recent study using ␣ 1 -AR knockout mice found that ␣ 1D -AR and ␣ 1D -/␣ 1B -AR knockout mice had a significant decrease in mean arterial blood pressure, whereas ␣ 1B -AR knockout mice did not, suggesting that ␣ 1D -/␣ 1B -ARs may act cooperatively to regulate blood pressure (Hosoda et al., 2005) . Additional evidence for a physiological role of ␣ 1B -AR/␣ 1D -AR heterodimers was provided from functional studies of isolated mouse carotid arteries, in which the potency of phenylephrine was significantly decreased in ␣ 1D -AR knockout mice yet unchanged in ␣ 1B -AR knockout mice ␣ 1B /␣ 1D -AR Heterodimers Form a Single Functional Entity (Deighan et al., 2005) . These findings raise the possibility that specific heterodimers respond supermaximally to agonist stimulation. Previous studies have reported that the formation of receptor heterodimers results in altered receptor functional characteristics (Breit et al., 2004; Lee et al., 2004) . Thus, another possibility is that ␣ 1B -/␣ 1D -AR heterodimers are responsible for activating novel transcriptional activators or mitogenic pathways. Future studies are needed to test this hypothesis. It is becoming increasingly clear that previously unexplained reports of altered pharmacological or functional characteristics of GPCRs may be explained by the formation of heterodimeric complexes. We have found that ␣ 1B -/␣ 1D -AR heterodimers mask BMY 7378 high-affinity ␣ 1D -AR binding sites, which may explain the inability of BMY 7378 to detect ␣ 1D -AR binding sites in native tissues coexpressing ␣ 1B -and ␣ 1D -ARs. These results raise the possibility that the number of pharmacologically distinct receptor subtypes may be greater than would be predicted by the number of GPCR genes. If true, the use of heterologous systems expressing a single GPCR to screen for novel therapeutics may not accurately reflect the pharmacological complexity of a drug in vivo.
